Voices
The Prevalence of ADC–Induced Nausea and Vomiting in Patients With Cancer – MASCC 
MASCC/LinkedIn

The Prevalence of ADC–Induced Nausea and Vomiting in Patients With Cancer – MASCC 

MASCC shared a post on LinkedIn:

“A new open-access publication from our Antiemetics and Emerging Toxicities Study Groups and led by Ronald Chow and colleagues looks at the prevalence of ADC–induced nausea and vomiting in patients with cancer.”

Title: Prevalence of antibody drug conjugated–induced nausea and vomiting (ADCINV) in patients with cancer

Authors: Ronald Chow, Daniel Zhang, Samy Kannout, Andreas Ma, Cindy Zheng, Ayden Blayne, Aaron Dou, Sumeet Talwar, Rouhi Fazelzad, Hope S. Rugo, Christina H. Ruhlmann, Hirotoshi Iihara, Mary Louise Affronti, Jennifer Leigh, Florian Scotté, Lawson Eng,
On Behalf of the MASCC Antiemetic Study Group and the MASCC Emerging Toxicities Study Group

Read the article

MASCC

Other articles about MASCC on OncoDaily.

Aaron Dou ADC ADCINV Andreas Ma Ayden Blayne cancer Christina H. Ruhlmann Cindy Zheng Daniel Zhang Florian Scotte Hirotoshi Iihara Hope S. Rugo Jennifer Leigh Lawson Eng Mary Louise Affronti MASCC MASCC Antiemetic Study Group MASCC Emerging Toxicities Study Group OncoDaily Oncology Ronald Chow Rouhi Fazelzad Samy Kannout Sumeet Talwar The Multinational Association of Supportive Care in Cancer